Business Context and Reporting Period
This Form 8-K is filed by Cyclacel Pharmaceuticals, Inc. (formerly Xcyte Therapies, Inc. following a March 27, 2006 acquisition of Cyclacel Limited) for the reporting period of May 14, 2006. The filing addresses a specific governance matter regarding the Company's Code of Business Conduct and Ethics.
Key Financial Metrics
The filing text does not provide clear values for revenue, profit, cash flow, margins, debt, or liquidity. The document focuses exclusively on a compliance waiver and does not contain financial performance data.
Material Changes
The material event reported is a one-time waiver of the Company's insider trading policy. On April 17, 2006, Spiro Rombotis, President and CEO, purchased 100 shares of common stock. This transaction occurred during a blackout period specified in the Code of Business Conduct and Ethics retained from Xcyte Therapies, Inc. The violation was deemed inadvertent as Mr. Rombotis was unaware the policy applied to the purchase.
Management Commentary and Risks
On May 17, 2006, the Audit Committee convened to review the transaction. The Committee determined that a waiver was appropriate due to the de minimis nature of the purchase (100 shares) and the inadvertent nature of the violation. The purchase was made for the purpose of monitoring the stock and ensuring timely distribution of corporate information. No other risks, contingencies, or unusual items are disclosed in this filing.
Investor Verification Points
- Confirm the total number of shares purchased by the CEO (100 shares) and the transaction date (April 17, 2006).
- Verify the Audit Committee's rationale for the waiver, specifically the "de minimis" classification.
- Review the Company's retained Code of Business Conduct and Ethics to understand the specific blackout period restrictions.
- Note that this filing contains no financial results; investors should refer to other filings for financial data.